Related Experiment Video
Updated: Jul 18, 2026

Pulsed Wave Doppler Assessment of Diastolic Dysfunction in the ZSF-1 Rat Model of Pulmonary Hypertension Due to Left Heart Disease
Published on: May 22, 2026
[Assessment of left ventricular diastolic function with pioglitazone in type 2 diabetic patients]
Gen Terui1, Takashi Goto, Mitsuaki Katsuta
1Department of Cardiovascular Medicine, Akita Red Cross Hospital. gterui@archosp-1998.com
Objectives:
This study investigated the effect of pioglitazone, an insulin sensitizer, on left ventricular diastolic function in type 2 diabetic patients.
Methods:
Various echocardiographic parameters such as left ventricular ejection fraction, transmitral E/A ratio (E/A), deceleration time of E, isovolumetric relaxation time and left ventricular Tei index were measured. A total of 59 patients were enrolled in the ON-group, and the parameters were examined before and after pioglitazone administration (15-30 mg/day) for 6 months, and 9 patients in the OFF-group, and the parameters were examined before and 6 months after cessation of pioglitazone.
Results:
Average age of subjects was 61.5 years with an age range from 45 to 79 years. Left ventricular ejection fraction and brain natriuretic peptide were not significantly changed both in the ON-group and in the OFF-group. Pioglitazone significantly increased E/A (0.91 +/- 0.23 vs 0.99 +/- 0.24, p < 0.01)and decreased deceleration time of E (233.9 +/- 58.6 vs 209.9 +/- 38.3 msec, p < 0.01), isovolumetric relaxation time(91.5 +/- 13.6 vs 76.0 +/- 12.1 msec, p < 0.01)and left ventricular Tei index (0.38 +/- 0.11 vs 0.35 +/- 0.09, p < 0.01) in the ON-group. On the other hand, E/A (1.08 +/- 0.35 vs 0.88 +/- 0.20, p < 0.01) was significantly decreased and left ventricular Tei index (0.28 +/- 0.11 vs 0.33 +/- 0.11, p < 0.01) was significantly increased in the OFF-group.
Conclusions:
Pioglitazone administration improves and cessation worsens left ventricular diastolic function.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Type II Diabetes II: Pathophysiology
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Oral Hypoglycemic Agents: Biguanides and Glitazones
Type I Diabetes II: Pathophysiology
Diabetes Mellitus: Type 2 and Gestational
